Quantitative Analysis of Complex Drug–Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data-Reference-Cited by-同舟云学术

Quantitative Analysis of Complex Drug–Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data

Published:2017-09 Issue:9 Volume:106 Page:2715-2726
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Kim Soo-Jin,Toshimoto Kota,Yao Yoshiaki,Yoshikado Takashi,Sugiyama Yuichi

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference38 articles.

1. Inhibition and induction of cytochrome P450 and the clinical implications;Lin;Clin Pharmacokinet,1998

2. Membrane transporters in drug development;Giacomini;Nat Rev Drug Discov,2010

3. Transporter mediated drug–drug interactions involving OATP substrates: predictions based on in vitro inhibition studies;Yoshida;Clin Pharmacol Ther,2012

4. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide;Bidstrup;Br J Clin Pharmacol,2003

5. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin;Kajosaari;Basic Clin Pharmacol Toxicol,2005

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay;Clinical Pharmacology & Therapeutics;2024-02-26

2. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil;Clinical Pharmacokinetics;2023-11-03

3. Neuroprotective effects of gemfibrozil in neurological disorders: Focus on inflammation and molecular mechanisms;CNS Neuroscience & Therapeutics;2023-10-30

4. Cluster Gauss‐Newton method for a quick approximation of profile likelihood: With application to physiologically‐based pharmacokinetic models;CPT: Pharmacometrics & Systems Pharmacology;2023-10-18

5. Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B;CPT: Pharmacometrics & Systems Pharmacology;2023-09-04